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Purpose: To study the feasibility of using Cherenkov luminescence imaging (CLI) to
evaluate and document ruthenium-106 plaque position during brachytherapy of uveal
melanoma.
Methods: Ruthenium-106 decays by emitting high-energy beta particles. When the
electrons pass through the eye, Cherenkov radiation generates a faint light that can
be captured by highly sensitive cameras. Patients undergoing ruthenium-106 plaque
brachytherapy for posteriorly located choroidalmelanomawere examinedbyCLI, which
was performed in complete darkness with an electron multiplying charged-coupled
device camera mounted on a fundus camera modified for long exposures.
Results: Ten patients with tumors ranging from 5.8 to 13.0 mm in largest basal diame-
ter and 2.0 to 4.6 mm in height were included. The plaques had an activity between
0.035 and 0.089 MBq/mm2 at the time of examination (1–4 days after implantation). CLI
revealed the actual plaque position by displaying a circular area of light in the fundus
corresponding with the plaque area. The Cherenkov light surrounded the tumor as a
halo, which showed some asymmetry when the plaque was slightly displaced. The light
intensity correlated positively with plaque activity and negatively with tumor pigmen-
tation. Exposure times between 30 and 60 seconds were required to display the plaque
position and delineate the tumor area. The long exposures made it difficult to maintain
stable eye fixation and optimal image quality.
Conclusions: CLI is a novel method to assess and document ruthenium-106 plaque
position in brachytherapy for uveal melanoma.
Translational Relevance: Ocular CLI may provide relevant radiation data during and
after implantation of radioactive plaques, thus improving the accuracy of episcleral
brachytherapy.
Introduction
Episcleral brachytherapy is currently the most
widely used conservative treatment for uveal
melanoma.1 Accurate radiation dosimetry and precise
placement of the radioactive plaque in relation to
the tumor are the two most important factors to
achieve local tumor control and to reduce the risk of
radiation-induced side effects.
Various techniques have been applied both intra-
operatively and postoperatively to ensure that the
attached radioactive plaque covers the tumor base
with the required tumor-free margin. During surgery,
indirect ophthalmoscopy with transscleral transillumi-
nation and different forms of ultrasound examina-
tion are commonly used.2–8 Ultrasound examination
is also the most common technique to assess plaque
placement after surgery.9–11 Other methods include
magnetic resonance imaging12,13 and the use of plaque-
mounted light-emitting diodes.14,15
For posteriorly located choroidal melanomas, it can
be challenging to position the plaque correctly, which
may explain why radiation failure is more common in
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such cases.16 Furthermore, initially well-placed plaques
may become displaced or tilted by eye movements,
hemorrhages, adjacent extraocular muscles, the optic
nerve sheath, or posterior ciliary nerves and vessels,
which in turn can decrease the radiation dose to the
tumor and cause local tumor recurrence.11,17 High-
resolution ultrasound examination can be used to
correctly determine plaque position during and after
surgery, but it might be hampered by varying image
resolution and imaging errors.18 Still, the development
of new methods to assess and document plaque place-
ment in episcleral brachytherapy is warranted.
Cherenkov luminescence imaging (CLI) is an
optical imaging modality that relies on the Cherenkov
radiation effect, where charged particles induce faint
visible light when travelling faster than the speed of
light through a dielectric medium.19 Ruthenium-106 is
a frequently used isotope for episcleral brachyther-
apy of uveal melanoma. Ruthenium-106 decays
with a half-life of 373.6 days via rhodium-106 to
palladium-106. Rhodium-106 has a half-life of about
30 seconds and emits highly energetic electrons with a
maximum energy of 3.5 MeV.20 Hence, the electrons
from rhodium-106 have sufficient energy to induce
Cherenkov radiation as they pass through the eyewall
and further into the vitreous. This phenomenon has
been shown in a recent in vitro study, where CLI
made it possible to verify the position and tilting of
ruthenium-106 plaques relative to melanin-containing
tumor phantoms in enucleated porcine eyes.20 The
emitted Cherenkov radiation varies over a wide range
in the visible spectrum with a peak in the ultraviolet–
blue region.21 In biological tissues, which favor the
transmission of red–infrared light, the emitted photons
are highly scattered and absorbed.21 The detection of
Cherenkov light in tissue is, therefore, challenging
and requires highly sensitive techniques, such as the
use of electron multiplying charged-coupled device
(EMCCD) cameras in completely dark environments.
Herein, we demonstrate the feasibility of using CLI
to assess and document the plaque position during
ruthenium-106 brachytherapy in patients with poste-
rior uveal melanoma.
Methods
Patients and Study Design
This prospective, clinical feasibility study was
conducted at the Department of Ophthalmology at
Haukeland University Hospital, which is one of two
national referral centers for ocular oncology. The study
was carried out between January 2018 and Novem-
ber 2019. Inclusion criteria were patients undergo-
ing ruthenium-106 plaque brachytherapy for choroidal
melanoma. The tumor had to be located so close to
the posterior pole that it could be visible in fundus
images within the limits of a 45° field of view. The
patients also had to be cooperative with CLI during
the early postoperative period. The decision as towhich
day should be selected for the examination was based
on practical considerations and the patient’s wishes and
general condition. Tumor pigmentation was subjec-
tively graded as weak, moderate, marked, or partial,
based on ophthalmoscopy and fundus photography.
The Cherenkov luminescence images were evaluated
according to their quality and ability to demonstrate
the plaque position relative to the tumor. Conventional
(Zeiss FF450; Carl Zeiss Meditec, Jena, Germany) and
ultra-widefield (California; Optos plc, Dunfermline,
Scotland, UK) fundus photography were performed
during follow-up to verify the actual plaque position
based on the radiation induced chorioretinal scar
formation.
In addition to the clinical CLI of uveal melanoma
patients, experimental CLI of ruthenium-106 plaques
placed in a water-filled container was performed to
optimize instrumentation performances and to visual-
ize the pattern of Cherenkov radiation generated in the
water adjacent to the plaque.
This study was registered and approved by the
Regional Committee for Medical and Health Research
Ethics, Western Norway (reference number: 2015/552),
and followed the official ethical regulations for clinical
research and the Declaration of Helsinki. All patients
gave their written informed consent before participa-
tion.
Ruthenium-106 Plaques and Surgical
Technique
The ruthenium-106 plaques used in the study were
of themodels CCA andCCB (Eckert &Ziegler BEBIG
GmbH, Berlin, Germany). These plaques have two
eyelets for surgical attachment and are circular with a
diameter of 15.3 mm and 20.2 mm. The diameter of
the radiation zone is slightly smaller than the diame-
ter of the plaque itself, leading to an annular inactive
rim of 0.75 mm. The mean plaque activity at the
time of CLI was 9.9 MBq (range, 7.0−12.8 MBq) and
15.8 MBq (range, 10.4−21.8 MBq) for the CCA and
CCB plaques, respectively. The prescription dose was
90 Gy to the tumor apex.
Surgery was performed under general anesthesia.
Plaque implantation was guided by indirect ophthal-
moscopy through a surgical microscope with slit-lamp
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attachment and a handheld contact lens (QuadrAs-
pheric; Volk Optical Inc.,Mentor, OH), combined with
fiber optic transscleral transillumination. The plaque
was secured to the sclera by two 7-0 silk sutures.
Owing to the posterior tumor location, all plaques were
positioned eccentrically (in the anteroposterior axis)
relative to the melanoma to decrease the radiation dose
to the fovea and optic disc. Therefore, the reported
plaque displacement in our patients did not apply to
the intended eccentric plaque location.
Instrumentation
The clinical CLI of uveal melanoma patients was
performed with an EMCCD camera coupled to a
fundus camera. For the experiments conducted in
2018, the images were acquired with the EMCCD
camera Andor iXon DV887 (Andor Technologies,
Belfast, Ireland), which from 2019 was replaced by
the upgraded Andor iXon Ultra 897. Both cameras
have a back-illuminated 8.2 × 8.2 mm sensor with the
capability of single photon detection and thermoelec-
tric cooling down to –90°C to –100°C to optimize sensi-
tivity and decrease dark current noise. The EMCCD
camera was connected to a personal computer and
attached to an analog 45° field of view fundus camera
system (KowaRC-XV2;Kowa, Tokyo, Japan)modified
to take long exposures (Fig. 1A). The software Andor-
SOLIS 64-bit (Oxford Instruments, Abingdon-on-
Thames, UK) was used for image acquisition and
storage.
For the experimental CLI of ruthenium-106
plaques, the EMCCD camera (Andor iXon Ultra
897) was focused on the plaque by means of two
achromatic optical lenses with a focal length of 60 mm
and 160 mm (Spindler &Hoyer, Gottingen, Germany),
respectively, placed in front of the camera. The 60-mm
lens was positioned one focal length from the plane of
the sensor, which was determined through the camera’s
real-time video function. The 160-mm lens was placed
one focal length from the plaque, and directly next
to the 60-mm lens. The ruthenium-106 plaque (CCB)
was put into a transparent acrylic box filled with
distilled water, and placed at different positions and
orientations relative to the EMCCD camera (Fig. 1B).
To eliminate any ambient light that would other-
wise lead to overexposure of the images, the CLI was
carried out in total darkness. This was achieved by
placing the instrumentation in a secluded part of the
hospital basement and keeping the fundus/EMCCD
camera and the connected computer in separate rooms.
For the same reason, the patient fixation light, which
consisted of a red light-emitting diode (LED) with a
peak wavelength of about 680 nm, was either dimmed
Figure 1. Photographs of the experimental setup. (A) The EMCCD
camera (arrow) mounted on the fundus camera for clinical CLI
of uveal melanoma patients. (B) The EMCCD camera and optical
systemused for experimental CLI ofwater-immersed ruthenium-106
plaques (arrow).
to aminimumor turned off during the imaging process.
For the clinical CLI conducted from 2019 onward,
a 600-nm short-pass filter (FES0600; Thorlabs Inc.,
Newton, NJ) was inserted into the EMCCD mount-
ing bracket directly in front of the camera sensor to
minimize the amount of ambient light from the LED
and thereby optimize eye fixation.
Image Processing
Before the experimental and clinical CLI, a reference
image of the ruthenium-106 plaque and fundus, respec-
tively, was acquired with a similar instrument setup and
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by operating the EMCCD without additional signal
amplification in low light conditions with exposure
times between 0.1 and 0.001 seconds.
The image acquisition settings for the clinical CLI
of patients with uveal melanoma were altered between
a few fixed values depending on various parameters
such as plaque activity, degree of tumor pigmenta-
tion, and the patient’s ability to cooperate during
CLI. The exposure time was set to 30, 45, or 60
seconds, mainly based on plaque activity (i.e., the
weaker the radioactivity, the longer the exposure time).
A hardware pixel binning of 2 × 2 or 4 × 4 was used
to optimize the sensitivity and signal-to-noise ratio. To
achieve sufficient image contrast, the electron multiply-
ing and pre-amplifier gains were set to 250× and 3×,
respectively.
Results
Experimental CLI of Ruthenium-106 Plaques
Two different setups were used to image the pattern
of Cherenkov radiation from the water-immersed
ruthenium-106 plaques. First, a CCB plaque with an
activity of 19.9 MBq was placed vertically to enable
front view imaging of its concave radioactive surface
(Fig. 2A). CLI of the plaque in this position revealed
a strong and homogenous emission of Cherenkov light
in the water fronting the concave surface of the plaque.
Despite a slightly lower light intensity at the periphery
of the plaque, corresponding with the annular inactive
rim, the light spread somewhat beyond the perime-
ter of the plaque (Fig. 2B). Second, a CCB plaque
with an activity of 17.2 MBq was placed horizon-
tally on the bottom of the acrylic box to enable side
view imaging (Fig. 2C). In this setup, the Cherenkov
light was clearly visible as a dome-shaped, luminous
area reaching just beyond the rim and about 8 to 10
mm above the edge of the plaque (Fig. 2D). When
visualized as a false-color coded image (Fig. 2E),
the light intensity gradually decreased with increasing
distance from the plaque, similar to the pattern seen
in a two-dimensional dose distribution diagram of a
CCB plaque with identical activity and radiation time
(Fig. 2F).
Clinical CLI of Uveal Melanoma Patients
Ten patients (4 men and 6 women) were included
in the study. Nine patients were Caucasians and
one patient was of East Asian ethnicity. The right
eye was involved in six patients and the left eye
in four patients. The mean age at the time of
Figure 2. Experimental CLI of the ruthenium-106plaques. (A) Front
view reference image, taken in low light conditions, of the concave
radioactive surface of a CCB plaque immersed in distilled water. (B)
Cherenkov luminescence image of the same plaque as shown in (A)
taken in total darknesswith anexposure timeof 30 seconds.Note the
homogenous emissionof Cherenkov light spreading slightly beyond
the plaque perimeter. (C) Side view reference image, taken in low
light conditions, of a CCB plaque immersed in distilled water. (D)
Cherenkov luminescence image of the same plaque as shown in (C)
taken in total darkness with an exposure time of 60 seconds. Note
the dome-shaped, luminous area reaching slightly beyond the rim
and 8–10 mm above the edge of the plaque. (E) False color-coded
version of the same image as shown in (D). The colors indicate the
relative light intensity, as given by the color scale at the bottom.
(F) Two-dimensional dose distribution diagram of a CCB plaque
with the same activity and radiation time as the plaque shown
in (D, E).
examination was 64 years (range, 39–80 years). All
tumors were dome-shaped and moderately elevated,
with a mean largest basal diameter of 9.7 mm
(range, 5.8–13.0 mm) and a mean height of 3.1
mm (range, 2.0–4.6 mm). Two tumors were weakly,
four were moderately, and two were markedly
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pigmented; two tumors were partially pigmented.
The mean plaque activity was 0.056 MBq/mm2
(range, 0.035–0.089 MBq/mm2) at the time of exami-
nation, which took place at a mean of 2 days after
plaque implantation (range, 1–4 days). The case
characteristics are presented in the Table.
Along with increasing experience, the methods for
CLI were slightly modified during the study period.
The red fixation LED combined with the integrated
short-pass filter was used in the latter part of the study
to improve the image quality. Further, the exposure
time had to be individually adjusted according to both
the plaque activity and the degree of tumor pigmen-
tation. Weakly pigmented tumors required shorter
exposure times to delineate the tumor area and, in some
cases, a reference fundus image was needed to assess
the plaque position in relation to the tumor. The level
of impulse noise, leading to so-called salt-and-pepper
pixels in the images, varied and was generally higher
in images of patients treated with low activity plaques
requiring long exposure times and a binning mode
of 2 × 2.
In all patients, CLI revealed a circular area of
light corresponding to the size and location of the
ruthenium-106 plaque. Because the anterior tumor
component was located outside the camera system’s
field of view, only the posterior part of the plaque and
tumor were included in the images. In most cases, the
tumor could be seen as a rounded, faintly darker area
surrounded by a halo of Cherenkov light.
In two patients (cases 5 and 6), only the ruthenium-
106 plaque, and not the tumor itself, could be identi-
fied in the CLI images. In eight patients, the image
quality was sufficient to assess the position of the
plaque relative to the tumor (Table). In five of
these patients, the plaque seemed to be somewhat
displaced. In case 4, the plaque was slightly decen-
tered temporally relative to the tumor, and in case 9,
the plaque was located somewhat inferior to the tumor
(Figs. 3A−C). An uneven intensity distribution of the
Cherenkov light was present in case 2 and 3, indicat-
ing a mild inferior and superior plaque tilt, respectively
(Figs. 4A−C). These assumptions were later confirmed
by examining the extent and degree of the chori-
oretinal scarring seen in the follow-up ultra-widefield
fundus photographs (Figs. 3D and 4D). Despite the
slight displacement of the plaques shown during treat-
ment, they adequately covered the tumor base. All
tumors included in the study regressed as expected after
ruthenium-106 brachytherapy, observed during amean
follow-up period of 13 months (median, 13.5 months;
range, 1−20 months).
The imaging procedures were generally easy to carry
out in clinical practice. Except for some tiredness
during long-exposure imaging, none of the patients
experienced discomfort or any negative side effects
during or after the examination.
Discussion
In this feasibility study, we have shown that CLI can
be performed in vivo as a novel method to evaluate
and document the position of ruthenium-106 plaques
during brachytherapy of posterior uveal melanoma. By
using an integrated EMCCD and fundus camera, we
were able identify the plaque in the fundus of all the
imaged patients. In most cases, it was also possible to
assess the position of the plaque relative to the tumor,
which appeared as a slightly darker area encircled by
the Cherenkov light. By looking at the symmetry and
intensity of the light distribution around the tumor,
assumptions could be drawn about possible plaque
dislocation, which was later confirmed by postopera-
tive fundus photography.
To take advantage of the CLI technique, a number
of difficulties had to be surmounted. In particular, the
patients’ ability to fixate and keep their eyes still during
long exposure imaging was crucial to achieve sufficient
image quality. The use of a fixation light combined
with an integrated short-pass filter to decrease the
amount of ambient light proved to be successful in
this regard. Although the diffuse plaque boundaries
in the Cherenkov luminescence images may be due to
unintentional eyemovements, it is probably to a greater
extent caused by the relatively strong light scattering
within the eyewall, especially in the scleral tissue.22
Another significant limitation of our technique is that
only a small part of the fundus is included in the
Cherenkov luminescence images, making it impossi-
ble to determine the position of the entire plaque.
However, this problemmay be solved by using a fundus
camera with a wider field of view combined with a
larger sized EMCCD sensor.
Heterogeneous tumor pigmentation was also a
challenge when analyzing the Cherenkov luminescence
images. Because melanin absorbs light at a wide range
of wavelengths,23 variations in melanin content may
lead to an emission pattern that differs from the
shape of the tumor. Likewise, possible differences in
tumor vascularization and the amount hemoglobinwill
affect the light emission owing to high absorption in
the blue–green wavelength range.24,25 The exposure
time was therefore adjusted based on the degree
of tumor pigmentation, because weakly pigmented
tumors required shorter exposures for visualization. In
cases where the tumor itself could not be identified,
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Figure 3. Fundus images of patients with posterior uveal melanoma. (A) Fundus photographs taken before ruthenium-106 plaque
brachytherapy. (B) Cherenkov luminescence images taken after implantation of the ruthenium-106 plaque. (C) The same images as in (B)
where the dashed white lines indicate the supposed plaque margin, and the dashed red lines delineate the area where the light is attenu-
ated by the pigmented tumor. (D) Ultra-widefield fundus images taken during follow-up to assess the actual plaque position based on the
radiation induced chorioretinal scar formation. The case numbers correspond to those listed in Table. In case 4, the plaque seems slightly
decentered temporally relative to the tumor. In case 9, the plaque is located somewhat inferior to the tumor.
a comparable reference image taken with the same
camera setup and the same field of view in low light
conditions was useful to display the tumor and judge
its location in relation to the plaque. Because there is
a linear relationship between the level of radioactivity
and the Cherenkov radiation,20 the necessary exposure
time was also adjusted according to plaque activity at
the time of imaging.
The experimental CLI of the ruthenium-106
plaques in water provided some interesting features of
the Cherenkov radiation. The emission was homoge-
neously distributed over the entire concave plaque
surface, and the light spread somewhat beyond the
borders of the plaque both in the front and side view
images. Most remarkable, when viewed from the side,
the Cherenkov light appeared as a dome-shaped,
luminous area above the plaque. Because the plaque
was immersed in distilled water, which is transparent
with low absorption and scattering coefficients,26,27
this phenomenon illustrates that the light is gener-
ated within the water itself and not projected from
the plaque surface. The similarity between the false
color-coded light intensity image and the regular dose
distribution diagram raises the question of whether it
is possible to determine the absorbed radiation dose
from the Cherenkov luminescence. As demonstrated
in previous studies, such an approach necessitates
rigorous camera calibrations and dose distribution
calculations.28,29
In the present study, CLI was performed to
assess and document ruthenium-106 plaque placement
during the postimplantation period. The main advan-
tage of CLI over other imaging modalities such as
B-scan ultrasound examination is that it provides an
en face view of the tumor and the plaque, which
makes it easier to determine the degree and direction
of plaque displacement. CLI may in principle also be
used intraoperatively to guide and monitor implanta-
tion of the plaque. However, this technique requires
new technical solutions to integrate the EMCCD
with the surgical microscope and to ensure absolute
darkness around the operating field. In addition to
ruthenium-106, other radioisotopes such as iodine-125
and palladium-103 are commonly used for episcleral
brachytherapy. In tissues with a refractive index of 1.4,
the electron energy threshold for Cherenkov radiation
is 0.219MeV.30 Ophthalmic plaques containing iodine-
125 or palladium-103 will not induce Cherenkov light
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Figure 4. Fundus images of patients with posterior uveal melanoma. The image details (A−D) are as described in Fig. 3. The case numbers
correspond to those listed in Table. In cases 2 and 3, the uneven intensity distribution of the Cherenkov light indicates a slight inferior and
superior plaque tilt, respectively. Note the less prominent chorioretinal scarring inferior to the tumor in case 2 and superior to the tumor in
case 3 (D).
because these radioisotopes emit gamma photons
with energies below the Cherenkov threshold in
tissue.29,31
In conclusion, the feasibility of in vivo CLI imaging
using an integrated EMCCD and fundus camera has
been demonstrated in a small group of patients under-
going ruthenium-106 plaque brachytherapy for poste-
riorly located choroidal melanoma. The overall image
quality differed markedly between the patients, and the
best images were obtained when CLI was performed
along with the use of a weak fixation light and the
integrated 600 nm short-pass filter in patients with
moderately tomarkedly pigmented tumors treatedwith
high activity plaques. Further refinement of the CLI
technique and the use of more sensitive cameras with
a wider field of view are needed to improve its clinical
usefulness, which will be explored in future studies.
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